Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The facility has the capacity to produce one crore doses per day
The company has to approach the DCGI for approval to commence the trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Filing for WHO Emergency Use Authorisation this month
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Subscribe To Our Newsletter & Stay Updated
